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MATURE B-CELL NEOPLASMS IN CHERNOBYL 
CLEAN-UP WORKERS OF 1986–1987: SUMMARY 
OF CYTOMORPHOLOGICAL AND IMMUNOCYTOCHEMICAL STUDY 
IN 25 YEARS AFTER CHERNOBYL ACCIDENT
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The data on the verified cases of mature B-cell neoplasms (chronic lymphocytic leukemia – CLL, B-prolymphocytic leukemia, non-
Hodgkin’s lymphoma in leukemization phase and multiple myeloma – MM; 146 cases in total) in the consecutive group of Ukrainian 
clean-up workers within 10–25 years after Chernobyl accident are summarized. B-cell neoplasms represent the most prevalent group 
among all diagnosed neoplasms of hematopoietic and lymphoid tissues in clean-up worker patients under study (49.4%). MM percentage 
in the patients of Chernobyl clean-up worker group turned out to be significantly higher than in the patients of the general populations 
studied at the same period. While the percentage of B-CLL is similar in clean-up worker patients and patients of general population, 
the trend towards younger age of patients with mature B-cell neoplasms in clean-up worker group is evident. The current concepts 
on the possible association between mature B-cell neoplasms (mainly B-CLL) and radiation exposure are briefly outlined. Only the 
precise diagnosis of hematopoietic malignancies combining with large-scale analytical epidemiological studies with careful dose assess-
ment and long-term follow-up may represent the basis for resolving the question whether mature B-cell neoplasms may be radiogenic.
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Chernobyl accident remains the worst in history 
of nuclear industry. Oncohematological consequences 
have been still very controversial, even in 25 years 
since the disaster.
The most intricate in this respect is the problem 
of the putative association between chronic lympho-
cytic leukemia (CLL) as well as other mature B-cell 
neoplasms and radiation exposure. CLL (and mature 
B-cell neoplasms in total) is one of the most prevalent 
forms of the tumors of hematopoietic and lymphoid 
tissues in the population of Europe and North America. 
Chernobyl accident has resulted in the radiation expo-
sure of the numerous group of population within the dif-
ferent dose range. Clean-up workers of 1986–1987 with 
the average dose estimate of approximately 100 mGy 
represent the most suffered group [1, 2].
Despite several research projects in Ukraine, Rus-
sian Federation and Belarus, the question whether the 
incidence of CLL among the exposed clean-up work-
ers has been still a point of controversy. The lack 
of database of verified diagnoses in most research 
presented within 25 years after Chernobyl accident 
is still a problem preventing from accurate analysis 
of the data by various epidemiological approaches. 
The aim of the study is to summarize the data on the 
verified cases of mature B-cell neoplasms (CLL, B-
prolymphocytic leukemia, non-Hodgkin’s lymphoma 
in leukemization phase and multiple myeloma) in the 
consecutive group of Ukrainian clean-up workers 
within 10–25 years after Chernobyl accident diag-
nosed in the Reference Laboratory representing the 
public service in RE Kavetsky Institute. The hemato-
poietic malignancies were diagnosed based on cyto-
morphology, cytochemistry and immunophenotyping 
in accordance with FAB, WHO, EGIL, ICD-10 and ICD-
O-2 classifications. 
Several aspects pertaining to the up-to-date views 
on the association between CLL and radiation expo-
sure are also briefly outlined. 
The research has been carried out within the 
framework of the collaboration with French-Ukrainian 
Center “Children of Chernobyl” set up in 1991 and 
Japanese-Ukrainian Leukemia/Lymphoma Study 
Group set up in 1998. 
PATIENTS AND METHODS
In all, 403 clean-up workers from Kyiv city and 
majority of the regional hospitals of Ukraine with sus-
pected oncohematological disorders were examined. 
All the clean-up workers referred to the Reference 
Laboratory in 1996–2010 were examined consecutively 
without any previous selection of the cases. The radia-
tion dose load of the clean-up workers under study 
varied from 75 to 250 mGy. The consecutive patients 
of general population aged over 30 (the total number 
of patients — 2697), mainly the residents of Kyiv city 
and district (hereinafter referred as “general popula-
tion”), diagnosed in the Reference Laboratory at the 
same period comprised the group of comparison. 
Bone marrow and peripheral blood smears stained 
by May-Grunwald-Giemsa were studied morphologi-
cally. Activities of myeloperoxidase, acid phosphatase 
(tartrate-sensitive and tartrate-resistant), non-specific 
esterase (sodium fluoride-sensitive), naphtol-AS-D-
chloracetate esterase, alkaline phosphatase were 
analyzed cytochemically. Glycogen was assayed 
cytochemically by PAS-reaction. Immunocytochemi-
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cal techniques (APAAP, LSAB-AP) and a broad panel 
of monoclonal antibodies (MoAbs) against lineage 
specific, differentiation and activation antigens of leu-
kocytes were employed for immunophenotyping patho-
logical cells in blood and bone marrow [3]. The main 
forms and cytological variants of hematological malig-
nancies were diagnosed according to FAB-classifica-
tion and REAL classification schemes. In 2001–2010 the 
diagnostic findings were revised in accordance with 
recently published new WHO classification [4]. 
RESULTS
In 118 of 403 patients in clean-up worker group, the di-
agnosis of tumors of hematopoietic and lymphoid tissues 
has not been confirmed. In 285 Chernobyl clean-up work-
ers various forms of malignant diseases of hematopoietic 
and lymphoid tissues were registered (see Table). 
Table. Summary of tumors of hematopoietic and lymphoid tissues diag-
nosed in Chernobyl clean-up workers (1996–2010)
Disease Number of cases and percentage
Mature B-cell neoplasms
Chronic lymphocytic leukemia 77 (26.10 %)
B-cell prolymphocytic leukemia 4 (1.36 %)
Hairy cell leukemia 11 (3.73 %)
Non-Hodgkin’s lymphoma in leukemization phase 35 (11.79 %)
Multiple myeloma 19 (6.44 %)
Mature T-cell neoplasms
T-cell prolymphocytic leukemia 2 (0.68 %)
T-cell large granular lymphocytic leukemia 5 (1.69 %)
Sezary syndrome 3 (1.02 %)
Myeloproliferative neoplasms
Chronic myelogenous leukemia 27 (9.01 %)
Polycythemia vera 6 (2.03 %)
Primary myelofibrosis 4 (1.36 %)
Essential thrombocythemia 10 (3.39 %)
Chronic eosinophIlic leukemia / eosinophilic syndrome 3 (1.02 %)
Myelodysplastic / myeloproliferative neoplasms
Chronic myelomonocytic leukemia 10 (3.39 %)
Myelodysplastic syndromes 16 (5.42 %)
Acute leukemias
Acute myeloid leukemia 46 (15.60 %)
Acute lymphoblastic leukemia 17 (5.76 %) 
The mature B-cell neoplasms constitute in total 
about half of all cases of tumors of hematopoietic and 
lymphoid tissues in our group of clean-up workers, 
namely 49.42%, with B-CLL being predominant form 
of mature B-cell neoplasms (26.10%). 
Immunophenotype of all B-CLL cases under study 
was quite typical (HLA-DR+, CD19+,  CD20+, CD22low, 
CD5+, CD23+, CD79a+, CD10–, sIglow).
B-cell prolymphocytic leukemia (B-PLL) was regis-
tered in 4 patients of clean-up worker group (1.36%) 
and 23 patients of general population group (0.85%). 
The phenotype of hairy cell leukemia (HCL) was 
(HLA-DR+, CD19+, CD20+, CD22+, CD5–, CD23–, CD10–, 
CD25+, sIgbright , κ+λ+) with relative frequency of 3.73% 
in clean-up workers and 4.73% in general population. 
Different types of B-cell non-Hodgkin’s lym-
phoma (NHL) in leukemization phase were diagnosed 
in 35 (11.79%) patients of Chernobyl clean-up worker 
group with 10.97% cases in general population. Tak-
ing into account the new WHO classification, follicular 
lymphoma was verified in 11 patients (CD19+, CD20+, 
CD22+, CD79a+, CD10+, CD5–, CD43–),  lymphoplas-
macytic lymphoma — in 7 patients (CD19+, CD20+, 
CD22+, CD79a+, CD38+, CD5–, CD10–, CD23–), mantle 
cell lymphoma — in 3 patients (HLA-DR+, CD19+, CD20+, 
CD22+, CD5+, cyclin D+, CD23–, CD10–). Splenic margin-
al zone B-cell lymphoma characterized in some cases 
by the abundance of villous lymphocytes exhibiting high 
tartrate-sensitive acid phosphatase activity (HLA-DR+, 
sIgbright, CD19+, CD20+, CD22+, CD5–, CD23–, CD10–, 
CD43–) was revealed in 5 patients. Diffuse large B-cell 
lymphoma (CD19+ CD20+ CD22+ CD79a+ CD5– CD22–) 
was revealed in 6 patients and extranodal marginal zone 
B-cell lymphoma of MALT type (CD19+ CD20+ CD22+ 
CD79a+ CD23–CD5– CD10–CD43+/–) — in 3 patients.
Multiple myeloma (MM) was diagnosed in 19 pa-
tients of clean-up worker group (6.44%). In 7 patients, 
the disease developed at the age below 50. Accord-
ing to the data of the available literature, the main 
peak of MM incidence could be registered at the age 
of 70–80. In our study, MM percentage in the pa-
tients of Chernobyl clean-up worker group turned out 
to be significantly higher than in the patients of the gen-
eral populations studied at the same period (4.00%). 
DISCUSSION
The data provided above seem to represent one 
of the attempts to characterize in details the major 
forms and cytological variants of mature B-cell neo-
plasms in Chernobyl clean-up workers that became 
evident in 10–25 years after their exposure to radia-
tion. The comparison of the relative distribution of the 
specified forms of mature B-cell neoplasms in the 
patients diagnosed among Chernobyl clean-up work-
ers demonstrates the increasing multiple myeloma 
rate while no differences in the percentage of NHL 
(in leukemization phase) and B-CLL between clean-
up workers and general population. 
A study of a cohort of 71,870 Russian-resident 
males who were engaged in recovery operations within 
30-km zone in 1986–1990 revealed a total of 58 mor-
phologically verified leukemia cases diagnosed in this 
cohort between 1986 and 1998, of which 16 cases 
(27.6%) were CLL [5]. In multinational case-control 
study in group of clean-up workers (1986–1987) from 
Belarus, Russia and Baltic countries, 32 (27.4%) cases 
of CLL and 34 (29.0%) cases of NHL were recorded 
[6]. In Ukrainian-American nested case-control study 
of leukemia and related disorders based on a cohort 
of 110,645 clean-up workers (1986–1990), the follow-
up (until 2000) has yielded 101 leukemia cases with 
49 (48.9%) CLL and 8 (7.93%) MM [7]. 
According to the data of the scientists from the 
Research Center for Radiation Medicine of the Na-
tional Academy of Medical Sciences of Ukraine, CLL 
in Chernobyl clean-up workers develops at younger 
age with more advanced symptoms and more aggres-
sive course and resistance to standard therapy [8]. 
The absence of demonstrable association between 
CLL in Japanese A-bomb survivors (partly due to the 
rarity of CLL among Japanese in general) and the results 
of earlier epidemiological studies in patients treated with 
radiation [9, 10] have led to the long persisted conclu-
sion that CLL is not associated with radiation exposure 
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[11, 12]. Nevertheless, recently these assumptions 
have been challenged. The epidemiological data based 
on studies in occupationally and medically exposed 
populations have required revising several aspects 
pertaining to CLL radiogenicity [11–15].
The clinical characteristics of CLL including its long 
latency and asymptomatic period, higher prevalence 
at older age, mild symptoms, and low rate of fatal 
outcomes resulted in underestimation of CLL judging 
by death certificates entries [13]. Many patients diag-
nosed with CLL often live for many years not requiring 
hospitalization and die from cases unrelated to their 
CLL (infectious or malignant diseases). 
Although CLL as the clinical and hematological 
entity is recognized for more than hundred years, only 
in the middle of 70-s of the last century this entity was 
introduced into International Classification of Diseases 
(ICD-8) [12] allowing for separate accounting for CLL 
and ALL incidence (in Ukraine such amendments came 
into force only in 1989). 
In research of the recent decade, new data on the 
origin and differentiation of B lymphocytes, the biol-
ogy of leukemic lymphocytes, and peculiar clinical 
features of B-CLL have been obtained. The specific 
immunophenotypic and molecular genetic features 
of B-CLL have become evident. As a result, the novel 
hypotheses on the origin and the evolution of this dis-
ease have been put forward. In parallel, the methods 
for the laboratory diagnosis have been improved. 
Earlier, CLL in majority of cases was considered 
to originate from naïve CD5+CD23+IgM+IgD+ B cells 
capable of recirculation and in some cases from CD5+ 
IgM+ subpopulation of memory B cells with mutation 
of IgHV genes. The results of the recent studies dem-
onstrate that in CLL the initial genetic impairments 
occur in immature B cells of bone marrow. The sub-
sequent repetitive antigenic stimulation with additional 
genetic lesions results in neoplastic transformation 
and leukemia development [16, 17]. Alternatively, the 
initiating events in CLL could occur in immature B cells 
circulating in peripheral blood, and in case of small 
lymphocytic lymphoma (SLL) — in similar B cells resid-
ing upon homing in lymph nodes or spleen.
One of the central points in pathogenesis of CLL 
is B cell receptor involved in transduction of signals 
associated with CLL cell microenvironment. The direct 
contact between B cells and accessory and stromal 
cells is also of high importance. 
CLL is known to exhibit stronger familial tendency 
than any other malignancy. CLL risk is 3-6-fold in-
creased in the relatives of CLL patients [12]. The role 
of hereditary factors in CLL is supported by the fact 
of strikingly low CLL incidence in China, Japan and 
Philippines. Such low CLL rates in Asians appear 
to be stable despite the migration of native popula-
tion to western countries [17]. Adverse environmental 
exposure including the infectious agents, antigens, 
genotoxic chemicals and ionizing radiation may also 
contribute substantially to CLL development [12].
Prior to REAL classification (1994) and WHO clas-
sification of tumors of hematopoietic and lymphoid 
tissues (2004, 2008), the strict criteria for differ-
entiating between B-CLL and other mature B cell 
neoplasms (B-cell prolymphocytic leukemia, hairy 
cell leukemia as well as nodular marginal zone lym-
phoma, follicular lymphoma and mantle cell lymphoma 
in leukemization phase) were lacking. Likewise, it was 
not possible to differentiate between B-CLL and rare 
T cell prolymphocytic leukemia, T-cell large granular 
lymphocytic leukemia, chronic lymphoproliferative 
disorder of NK cells. In this respect, monoclonal B-
cell lymphocytosis (MBL) as the condition that may 
precede CLL deserves close attention [18]. In MBL, 
immunophenotype and the chromosomal abnor-
malities are similar to those of CLL. MBL is detected 
up to 5% of adult population depending on their age 
distribution. In this connection, the assay of pheno-
typic subpopulations of lymphocytes by flow cytometry 
seems to be of high importance in periodical laboratory 
examination of blood in clean-up workers.
We suppose that the integration of CLL and SLL into 
one nosological group referred to as CLL/SLL seems 
rather unwarranted since the term SLL is used mainly 
by hematopathologists for non-leukemic cases with 
histopathology and immunophenotype correspond-
ing to that of CLL. This question may complicate the 
epidemiological studies involving such entity.
For many years, CLL cases have been underes-
timated. Even as late as in 1975, for diagnosing CLL 
lymphocyte count over 15 x 109/L was required. There-
fore, many low count cases have gone unrecognized. 
At present, the diagnostic criteria for CLL is formulated 
as ≥  5 x 109/L monoclonal lymphocytes with CLL phe-
notype in peripheral blood.
In 70–80s of the last century, the first reports de-
scribing specific chromosomal translocations in CLL 
begin to appear. At present, the broad spectrum 
of cytogenetic and molecular biological alterations 
are known to be associated with CLL development.
The heterogeneity of the clinical manifestations 
in CLL depends largely on the differences in the muta-
tional status of variable regions of the genes of heavy 
chains of immunoglobulins (IgHV). Somatic mutations 
of IgHV genes are detected in more than 50–60% of CLL 
cases [16, 17]. The absence of the somatic mutations 
and presence of CD38 and ZAP-70 expression appear 
to be associated with more unfavorable course of the 
disease. Mutations in several other genes such as BCL6, 
MYC, PAX5 and RHOH also modify the course of the dis-
ease in the patients with non-mutated immunoglobulin 
genes. In the stable course of the disease in patients 
with somatic mutations of IgHV genes, overexpression 
of WNT3, CTLA4, ADAM29, TCF7 is evident [17].
Some of the somatic mutations in CLL may 
be a consequence of the environmental exposures 
[11]. The clonal chromosomal aberrations are revealed 
in 50–80% of CLL cases [16, 17]. About half of CLL pa-
tients with clonal chromosomal abnormalities are the 
carriers of one abnormality while there are at least two 
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genetic abnormalities in another half of the patients. 
The use of FISH technique allows for clarifying the 
frequencies of the most prevalent chromosomal aber-
rations in CLL. The most common are 13q14 deletion, 
trisomy 12 and 11q22-q23 deletion while 6q21 and 
7p13 deletions are less prevalent [12, 13]. It is impor-
tant that the most common 13q14 deletion involves 
the region covering two micro RNA genes, mir15 and 
mir16 [19]. These micro RNA may be important for 
regulating the functions of genes which may have rel-
evance to cancer in general and CLL in particular [20]. 
The above mentioned micro RNA genes have been 
shown to be deleted or down-regulated in most cases 
of CLL [21]. It seems that this deletion confers a selec-
tive advantage possibly predisposing B-cell clones 
to undergo additional mutations via regulatory path-
ways involving key oncogenes [22]. Since mir15 and 
mir16 normally interact with BCL6, their absence in CLL 
may be important for preventing apoptosis. 
In some CLL patients, trisomy 12 may be detected 
in 25–72% of malignant cells [16, 17]. At present, the 
genes of chromosome 12 that may facilitate leukemic 
transformation upon increase in copy number have 
not been identified. The cases of CLL with the partial 
trisomy 12 limited by the long arm seem to be useful 
clue in identifying such genes since this chromosomal 
region contains several genes coding for growth fac-
tors which may well be the putative genes involved 
in the development of CLL [16, 17]. It is also of high 
importance that 12q22 region contains CLLH1 gene 
that is the first gene recognized as CLL-specific.
11q22-q23 deletion is a characteristic feature 
of peculiar CLL variant [23, 24]. The detailed map-
ping of 11q22.3-q23.1 region revealed the minimal 
deletion area containing NPAT, CUL5, PPP2RIB, DDXP 
genes known to be involved in controlling cell cycle 
and apoptosis. The same region contains ATM gene 
considered as caretaker of genome and playing a role 
in DNA-damage recognition and signaling. ATM gene 
is responsible for inherited autosomal recessive dis-
order ataxia teleangiectasia considered as a marker 
for cancer predisposition [25] with neoplasms of the 
lymphoid system being predominant [26]. When ATM 
mutation affects both ATM alleles, a risk of leukemia 
is approximately 70 times higher than in general 
population [27]. The presence of somatic mutations 
of ATM gene in the cells of CLL patients suggests their 
possible role in CLL pathogenesis.
The first report of ATM involvement in sporadic B-
CLL was published in 1999 [28]. Several other studies 
reported similar evidence for ATM role in CLL [29, 30]. 
50% of ATM mutations affect phosphatidylinositol 3-ki-
nase domain of ATM protein which is highly conserved 
among ATM-related proteins and crucial for protein 
kinase activity of ATM [25]. 
Sometimes, 17p13 deletion is detected in leukemic 
cells of CLL patients. This is the region wherein p53 gene 
is localized. The role of p53 for apoptosis induction 
in cells in response to their damage is well known. In this 
context, it is important that 10–20% cases of CLL with 
resistance to therapy and unfavorable prognosis dem-
onstrate the abnormalities of p53 [23, 24]. 
6q deletion in CLL is considered as secondary one 
being associated with other chromosomal aberrations.
Recently, the epigenetic alterations including DNA 
methylation patterns have been also considered in the 
pathogenesis of CLL [31, 32]. 
To sum up, the current understanding of the patho-
genesis of CLL has challenged the previous views 
on the absence of association between mature B-cell 
neoplasms and radiation exposure. Only the precise 
diagnosis of hematopoietic malignancies combining 
with large-scale epidemiological studies with careful 
dose assessment and long-term follow up may repre-
sent the basis for resolving the question whether CLL 
may be radiogenic as well.
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